Sterne Kessler Advises IntraBio in $2 Billion Sale to Shionogi

Washington, D.C. (October 6, 2026) – A team from Sterne, Kessler, Goldstein & Fox advised IntraBio Inc. on intellectual property matters in connection with an agreement to sell the company to Japanese pharmaceutical company Shionogi & Co., Ltd. IntraBio, based in Austin, Texas, develops therapies for neurodegenerative diseases. Shionogi will acquire all outstanding shares of IntraBio for upfront consideration of $2 billion payable to IntraBio shareholders.

As part of the deal, IntraBio will become a wholly owned subsidiary of Shionogi Inc., a New Jersey-based subsidiary of Shionogi. The proposed transaction, subject to customary closing conditions, would add IntraBio’s global rights for AQNEURSA (levacetylleucine), including intellectual property rights, to Shionogi’s growing rare disease portfolio.

The Sterne Kessler team that advised IntraBio was led by Directors Paul Ainsworth and Jeremiah B. Frueauf. They were joined by Director Mick Gross, Counsel Shana Olson, and Associates Lisa Ritchey, Calvin Mendel, and Matthew Swazer.

Learn more about the Shionogi-IntraBio transaction.

About Sterne, Kessler, Goldstein & Fox

Based in Washington, D.C., Sterne Kessler is a leading intellectual property law firm providing strategic IP services to clients worldwide. With more than 170 attorneys, the firm offers integrated capabilities across patent and trademark prosecution, strategic counseling, post‑grant proceedings, and litigation before federal district and appellate courts and the International Trade Commission. Since 1978, Sterne Kessler has served as a trusted partner to innovative companies, startups, inventors, universities, and investors, helping them protect, enforce, and maximize the value of intellectual property. The firm is committed to delivering practical, business‑driven solutions that support innovation and long‑term strategic objectives.